Previous 10 | Next 10 |
TORRANCE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari®...
Gainers: LMP Automotive (NASDAQ: LMPX ) +95% . More news on: LMP Automotive Holdings, Inc., Sarepta Therapeutics, Inc., Cohen & Company Inc., Stocks on the move, Read more ...
Emmaus Life Sciences ( OTC:EMMA ): Q3 GAAP EPS of -$0.60. Revenue of $6.08M (+24.6% Y/Y) Press Release More news on: Emmaus Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
-- Net Revenues Increased 25% Year-Over-Year, Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities -- TORRANCE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment,...
Company Enters Into Common Stock Purchase Agreement with Vivozon, Inc. TORRANCE, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that Vivozon, Inc. has executed a stock purchase agreement for...
TORRANCE, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease (SCD) treatment, today reported preliminary gross sales results of $7.0 million for the third quarter ended September 30, 2019 compared to $6.2 million for the sec...
TORRANCE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the allowance by the Indian Patent Office of its patent application (serial number 1255/KOLNP/2014) for methods and compositions of pharma...
Emmaus Life Sciences ( OTC:EMMA +2.5% ) common stock trades on the OTCQB marketplace, effective September 26, 2019. More news on: Emmaus Life Sciences, Inc., Read more ...
TORRANCE, Calif. , Sept. 26, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it is approved to have its common stock trade on the OTCQB marketplace, effective September 26, 2019 . The common stock of Em...
Gainers: Emmaus Life Sciences ( OTC:EMMA ) +64% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +23% . SYNNEX Corporation (NYSE: SNX ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +17% . R.R. Donnelley & Sons Company (NYSE: RRD ) +16% . Comtech Telecommunications (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Emmaus Life Sciences Incorporation Company Name:
EMMA Stock Symbol:
NYSE Market:
Emmaus Life Sciences Incorporation Website:
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program PR Newswire TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceuti...
Emmaus Life Sciences Reports 2023 Financial Results PR Newswire TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today r...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...